Replay Conf call - Janssen deal & Replay Webcast - ITP Ph2 & AML Ph1/2 data

Discovery programs

Using our SIMPLE Antibody™ technology, we have created libraries of specific antibodies against multiple and diverse targets of therapeutic relevance.

We continue to focus on novel, complex targets with functional involvement in cancer and severe autoimmune diseases.